Business
OWC Israel's Patent for Cannabis Based Extracts and Topical Formulations for Use in Skin Disorders, Is Allowed for Issuance as a Patent in the USA
OWC Israel's Patent for Cannabis Based Extracts and Topical Formulations for Use in Skin Disorders, Is Allowed for Issuance as a Patent in the USA.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Israel's Patent for Cannabis Based Extracts and Topical Formulations for Use in Skin Disorders, Is Allowed for Issuance as a Patent in the USA\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOWC Israel's Patent for Cannabis Based Extracts and Topical Formulations for Use in Skin Disorders, Is Allowed for Issuance as a Patent in the USA\nPR Newswire\nRAMAT GAN, Israel, Dec. 16, 2019\n\n\n\nRAMAT GAN, Israel, Dec. 16, 2019 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP) (\"OWC\"), represented by its wholly-owned subsidiary, One World Cannabis Ltd., a company organized and existing under the laws of Israel (\"OWC-Israel\"), announced that, on December 9, 2019, the United States Patent and Trademark Office issued a Notice of Allowance indicating that OWC Israel's Patent Application No. 15/629,230 directed to cannabis based extracts and topical formulations for use in skin disorders, is allowed for issuance as a patent. The allowed patent application, which indicates a unique modality of treatment, covers a method of treating or inhibiting an inflammatory skin disease in a human in need thereof comprising topically administering to the human a therapeutically effective amount of a pharmaceutical composition comprising carrier formulations described in the claims and cannabis oil comprising cannabidiol and tetrahydrocannabinol, wherein the inflammatory skin disease is selected from a large group of skin conditions, including but not limited to psoriasis.\nSkin disorders are a key focus area for OWC's clinical development program. OWC has performed pre-clinical studies and has completed a human safety study with a cannabis-based ointment and is in the process of procuring the necessary permits for an efficacy study on psoriatic patients.\nThis allowed US patent application adds significantly to OWC's intellectual property portfolio, which includes issued patents for treatment of skin conditions in the Czech Republic and Australia, as well as other families of patent applications currently under prosecution, directed to the use of cannabis-b...